Warning: The NCBI web site requires JavaScript to function. more...
Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study.
Vonkeman HE, Braakman-Jansen LM, Klok RM, Postma MJ, Brouwers JR, van de Laar MA.
Arthritis Res Ther. 2008;10(6):R144. Epub 2008 Dec 16.
Related citations
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.
Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.
Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.
Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
Vonkeman HE, Fernandes RW, van der Palen J, van Roon EN, van de Laar MA.
Arthritis Res Ther. 2007;9(3):R52.
Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study.
Knijff-Dutmer EA, Postma MJ, van der Palen J, Brouwers JR, van de Laar MA.
Clin Ther. 2004 Jul;26(7):1160-7.
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
El-Serag HB, Graham DY, Richardson P, Inadomi JM.
Arch Intern Med. 2002 Oct 14;162(18):2105-10.
[Cost comparative analysis of drug therapy for non-steroidal anti-inflammatory drug (NSAID)-induced gastric ulcer in Japan].
Hashiguchi M, Yamauchi N, Uchikura T, Mochizuki M.
Yakugaku Zasshi. 2008 Apr;128(4):585-94. Japanese.
Management of NSAID-induced gastrointestinal toxicity: focus on proton pump inhibitors.
Lazzaroni M, Porro GB.
Drugs. 2009;69(1):51-69. doi: 10.2165/00003495-200969010-00004. Review.
Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding.
Edelson JT, Tosteson AN, Sax P.
JAMA. 1990 Jul 4;264(1):41-7.
Prevention of NSAID-induced gastroduodenal ulcers.
Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J.
Cochrane Database Syst Rev. 2002;(4):CD002296. Review.
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE, Metge CJ, Leung S, Chateau DG.
Gastroenterology. 2008 Apr;134(4):937-44. Epub 2008 Jan 11.
The cost effectiveness of misoprostol prophylaxis alongside long-term nonsteroidal anti-inflammatory drugs. Implications of the MUCOSA trial.
Davey PJ, Meyer E.
Pharmacoeconomics. 2000 Mar;17(3):295-304.
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.
BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.
[Cost effectiveness of misoprostol therapy in prevention of NSAID-induced stomach ulcers].
Schwarz B.
Wien Klin Wochenschr. 1995;107(12):366-72. German.
[Prevention of NSAID induced gastroduodenal ulcers].
Hansen JM, Bytzer P.
Ugeskr Laeger. 2001 Oct 29;163(44):6103-5. Danish.
Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.
Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Walton S, Goldstein JL.
Aliment Pharmacol Ther. 2003 Dec;18(11-12):1137-47.
Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002.
Hermansson M, Ekedahl A, Ranstam J, Zilling T.
BMC Gastroenterol. 2009 Apr 20;9:25.
Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A, Mészáros A.
Int J Technol Assess Health Care. 2009 Apr;25(2):190-5.
Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan.
Ishikawa S, Inaba T, Mizuno M, Okada H, Kuwaki K, Kuzume T, Yokota H, Fukuda Y, Takeda K, Nagano H, Wato M, Kawai K.
Acta Med Okayama. 2008 Feb;62(1):29-36.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on